H-Ala-NHBu | 42461-01-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-Ala-NHBu
• 英文别名: (S)-2-amino-N-butylpropanamide；N-Butyl-L-alaninamid；L-Alanin-butylamid；(2s)-2-Amino-N-Butyl-Propanamide；(2S)-2-amino-N-butylpropanamide
• CAS: 42461-01-8
• 化学式: C₇H₁₆N₂O
• 分子量: 144.217
• InChiKey: XXYQJGUBGFEJMV-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  H-Ala-NHBu 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 乙二醇二甲醚 、 水 、 异丙醇 为溶剂， 反应 4.5h， 生成 (S)-N-butyl-2-((6-(6-methoxypyridin-3-yl)quinazolin-4-yl)amino)propanamide
  参考文献：
  名称：

  4-氨基酸侧链取代的喹唑啉衍生物及其应用

  摘要：

  本发明公开了一类具有PI3K抑制活性的6‑(吡啶‑4‑基)‑4‑取代氨基的喹唑啉和喹啉类化合物，其为具式(I)结构的化合物或其药学上可接受的盐的溶剂合物、对映异构体、非对映异构体、互变异构体或其任意比例的混合物，包括外消旋混合物。该类化合物对PI3K具有良好的抑制作用，展现出良好的抗肿瘤效果，具有制备用于治疗对PI3Kδ和/或PI3Kα有响应的疾病的药物的前景。本发明还涉及这些化合物可以作为PI3K抑制剂的医药用途。

  公开号：

  CN114292259B
• 作为产物：
  描述：

  9H-fluoren-9-ylmethyl N-[(2S)-1-(butylamino)-1-oxopropan-2-yl]carbamate 在 哌啶 作用下， 以 氯仿 为溶剂， 反应 12.0h， 生成 H-Ala-NHBu
  参考文献：
  名称：

  Pore-Forming Monopeptides as Exceptionally Active Anion Channels

  摘要：

  We describe here a unique family of pore-forming anion transporting peptides possessing a single-amino-acid-derived peptidic backbone that is the shortest among natural and synthetic pore-forming peptides. These monopeptides with built-in H-bonding capacity self-assemble into an H-bonded 1D columnar structure, presenting three types of exteriorly arranged hydrophobic side chains that closely mimic the overall topology of an alpha-helix. Dynamic interactions among these side chains and membrane lipids proceed in a way likely similar to how a-helix bundle is formed. This subsequently enables oligomerization of these rod-like structures to form ring-shaped ensembles of varying sizes with a pore size of smaller than 1.0 nm in diameter but sufficiently large for transporting anions across the membrane. The intrinsic high modularity in the backbone further allows rapid tuning in side chains for combinatorial optimization of channel's ion-transport activity, culminating in the discovery of an exceptionally active anion-transporting monopeptide 6L10 with an EC50 of 0.10 mu M for nitrate anions.

  DOI：

  10.1021/jacs.8b04657
• 作为试剂：
  描述：

  苯甲醛 、 alpha-氯乙酰苯 在 sodium hydroxide 、 H-Ala-NHBu 作用下， 以 水 、 甲苯 为溶剂， 反应 576.0h， 以90%的产率得到(2S,3R)-2,3-epoxy-1,3-diphenylpropan-1-one
  参考文献：
  名称：

  Julia, Sebastian; Guixer, Joan; Masana, Jaume, Journal of the Chemical Society. Perkin transactions I, 1982, p. 1317 - 1324

  摘要：

  DOI：

文献信息

• Pd-Catalysed oxidative carbonylation of α-amino amides to hydantoins under mild conditions
  作者：Aleksandr Voronov、Vinayak Botla、Luca Montanari、Carla Carfagna、Raffaella Mancuso、Bartolo Gabriele、Giovanni Maestri、Elena Motti、Nicola Della Ca

  DOI：10.1039/d1cc04154a

  日期：——

  The first example of palladium-catalysed oxidative carbonylation of unprotected α-amino amides to hydantoins is described here. The selective synthesis of the target compounds was achieved under mild conditions (1 atm of CO), without ligands and bases. The catalytic system overrode the common reaction pathway that usually leads instead to the formation of symmetrical ureas.

  这里描述了钯催化氧化羰基化未保护的 α-氨基酰胺为乙内酰脲的第一个例子。目标化合物的选择性合成是在温和条件下（1 atm CO）实现的，无需配体和碱。催化系统超越了通常导致形成对称尿素的常见反应途径。
• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。
• Amino Acids and Peptides. VI. Novel Peptide Bond Formation catalyzed by Metal Ions. IV. Formation of optically Active Amino Acid Amides and Peptide Amides
  作者：MITSUYOSHI WAGATSUMA、SHIRO TERASHIMA、SHUN-ICHI YAMADA

  DOI：10.1248/cpb.21.422

  日期：——

  The Cu (II)-catalyzed peptide bond formation previously reported by us, was applied to the synthesis of optically active amino acid amides and peptide amides. Treatment of an optically active amino acid ester with a primary amine in the presence of anhydrous CuCl2 afforded the desired amino acid secondary amide, without racemization, in 60-70% yield. However, the same reaction with a secondary amine with larger steric hindrance than primary amine gave an optically active tertiary amide in a very low yield as expected from the proposed mechanism. Almost all the amino acid amides could be isolated as hydrochlorides or as free bases. Some peptide amides, i. e. Z-Gly-Gly-NH-Bzl, and Z-Ala-Gly-NH-Bzl, were also prepared.

  我们之前报道的Cu(II)催化肽键形成反应，被应用于光学活性氨基酸酰胺和肽酰胺的合成。在无水CuCl2的存在下，将光学活性氨基酸酯与一级胺反应，可以获得所需的氨基酸次级酰胺，且未发生消旋化，产率为60-70%。然而，与具有比一级胺更大空间位阻的二级胺进行相同反应，根据提出的机理预期，得到的光学活性三级酰胺产率非常低。几乎所有的氨基酸酰胺都可以分离为盐酸盐形式或游离碱形式。一些肽酰胺，例如Z-Gly-Gly-NH-Bzl和Z-Ala-Gly-NH-Bzl，也被制备出来。
• Structure-Based Design, Synthesis, and Memapsin 2 (BACE) Inhibitory Activity of Carbocyclic and Heterocyclic Peptidomimetics
  作者：Stephen Hanessian、Hongying Yun、Yihua Hou、Gaoqiang Yang、Malken Bayrakdarian、Eric Therrien、Nicolas Moitessier、Silvio Roggo、Siem Veenstra、Marina Tintelnot-Blomley、Jean-Michel Rondeau、Christian Ostermeier、André Strauss、Paul Ramage、Paolo Paganetti、Ulf Neumann、Claudia Betschart

  DOI：10.1021/jm050142+

  日期：2005.8.1

  BACE led to the design and synthesis of a series of constrained P(1)' analogues. A cyclopentane ring was incorporated in 1 spanning the P(1)' Ala methyl group and the adjacent methylene carbon atom of the chain. Progressive truncation at the P(2)'-P(4)' sites led to a potent truncated analogue 5 with good selectivity over Cathepsin D. Using the same backbone replacement concept, a series of cyclopentane

  基于BACE的Tang-Ghosh七肽抑制剂1（OM99-2）的X射线晶体结构的分子建模，导致设计和合成了一系列受约束的P（1）'类似物。1个环戊烷环结合在P（1）'Ala甲基和该链的相邻亚甲基碳原子上。在P（2）'-P（4）'位点的逐步截短导致有效的截短的类似物5，对组织蛋白酶D具有良好的选择性。使用相同的骨架替换概念，一系列环戊烷，环戊酮，四氢呋喃，吡咯烷和吡咯烷酮合成的类似物在P和P'位点有相当大的变化。环戊酮和2-吡咯烷酮类似物45和57显示出较低的nM BACE抑制作用。
• Carboxyalkyl peptide derivatives
  申请人：G.D. Searle & Co.

  公开号：US04511504A1

  公开（公告）日：1985-04-16

  This invention encompasses novel carboxyalkyl peptide derivatives which are collagenase inhibitors.

  这项发明涵盖了一种新型的羧基烷基肽衍生物，它们是胶原酶抑制剂。